Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation

The risks of thromboembolic and hemorrhagic events in patients with atrial fibrillation both increase with age; therefore, net clinical benefit analyses of anticoagulant treatments in the elderly population are crucial to guide treatment. We evaluated the 1-year clinical outcomes with non-vitamin-K antagonist and vitamin K antagonist oral anticoagulants (NOACs vs VKAs) in elderly ( ≥75 years) patients with atrial fibrillation in a prospective registry setting.

Source: The American Journal of Medicine - January 18, 2019 Category: General Medicine Authors: Giuseppe Patti, Ladislav Pecen, Markus Lucerna, Kurt Huber, Miklos Rohla, Giulia Renda, Jolanta Siller-Matula, Fabrizio Ricci, Paulus Kirchhof, Raffaele De Caterina Tags: Clinical Research Study Source Type: research